CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

* ≤ 26-years old at the time of the first CAR treatment
* Receipt of a CD19-containing CAR T-cell product (investigational or commercial) for B- ALL
* Receipt of one unique CAR product (reinfusion of same product allowed)
* Sustained remission without subsequent therapy post-CAR (exception= post-CAR consolidative HCT)
* Receipt of only one prior HCT (inclusive of pre- or post-CAR)
* ≥ 2-years post last CAR T-cell infusion

Exclusion Criteria:

* Inability or unwillingness of research participant or legal guardian/representative to give written informed consent

主要终点：To evaluate the feasibility of conducting standardized clinical assessments of pediatric and AYA B-ALL survivors post CD19-CAR T-cell therapy · Estimation of participation rate · Through study completion, approximately 5 years

To learn more about the long-term health in patients treated for B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Cluster of Differentiation antigen 19 (CD19) -redirected chimeric antigen receptor (CAR) T-cells. Primary Objective: To evaluate the feasibility of conducting standardized clinical assessments of pediatric, adolescent and young adult (AYA) B-ALL survivors post CD19-CAR T-cell therapy, treated at multiple institutions, leveraging the St Jude Lifetime Cohort (SJLIFE) clinical and research infrastructure. Exploratory Objectives: * To describe the prevalence of persistent and new/late-onset health conditions developing ≥2-years post CD19-CAR T-cell therapy in survivors of pediatric and AYA B-ALL. * To characterize neurocognitive and neurologic function in survivors ≥2-years post CD19- CAR T-cell therapy. * To characterize immune health in survivors ≥2-years post CD19-CAR T-cell therapy. * To characterize functional status in survivors ≥2-years post CD19-CAR T-cell therapy.